Invivyd, Inc. (ADGI)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Invivyd, Inc. (ADGI)
Company Performance

Current Price

as of Oct 18, 2024

$0.97

P/E Ratio

N/A

Market Cap

$115.47M

Description

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Metrics

Overview

  • HQWaltham, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerADGI
  • Price$0.9667-7.93%

Trading Information

  • Market Cap$115.47M
  • Float60.82%
  • Average Daily Volume (1m)386,265
  • Average Daily Volume (3m)457,090
  • EPS-$1.80

Company

  • Revenue$2.26M
  • Rev Growth (1yr)N/A
  • Net Income-$47.25M
  • Gross Margin73.41%
  • EBITDA Margin-2,152.52%
  • EBITDA-$48.73M
  • EV-$15.90M
  • EV/Revenue-7.02
  • P/EN/A
  • P/S50.97
  • P/B0.82
Documents